User login
Key clinical point: Guselkumab 100 mg every 4 weeks (Q4W) or 8 weeks (Q8W) provided a clinically meaningful reduction in fatigue in patients with active psoriatic arthritis (PsA).
Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W (63%; P less than .001) and Q8W (54%; P less than .01) vs placebo (35%) achieved 4-point or higher improvement in Functional Assessment of Chronic Illness Therapy-Fatigue scores in DISCOVER-1. Findings were similar with guselkumab Q4W (60%; P less than .01) and Q8W (61%; P less than .001) vs placebo (46%) in DISCOVER-2. Improvements were maintained until week 52.
Study details: Findings are from the analysis of 2 phase 3 trials (DISCOVER 1 and DISCOVER 2) including 1,120 patients with active PsA who were randomly assigned to guselkumab 100 mg at week 0 and then Q4W, guselkumab 100 mg at weeks 0 and 4 and then Q8W, or placebo Q4W.
Disclosures: This study was funded by Janssen Research & Development, LLC. Some of the authors declared receiving grants, consulting fees, and speaker’s bureau support from various sources including Janssen. Seven of the authors declared being employees and stockholders of Johnson & Johnson.
Source: Rahman P et al. Arthritis Res Ther. 2021 Jul 14. doi: 10.1186/s13075-021-02554-3.
Key clinical point: Guselkumab 100 mg every 4 weeks (Q4W) or 8 weeks (Q8W) provided a clinically meaningful reduction in fatigue in patients with active psoriatic arthritis (PsA).
Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W (63%; P less than .001) and Q8W (54%; P less than .01) vs placebo (35%) achieved 4-point or higher improvement in Functional Assessment of Chronic Illness Therapy-Fatigue scores in DISCOVER-1. Findings were similar with guselkumab Q4W (60%; P less than .01) and Q8W (61%; P less than .001) vs placebo (46%) in DISCOVER-2. Improvements were maintained until week 52.
Study details: Findings are from the analysis of 2 phase 3 trials (DISCOVER 1 and DISCOVER 2) including 1,120 patients with active PsA who were randomly assigned to guselkumab 100 mg at week 0 and then Q4W, guselkumab 100 mg at weeks 0 and 4 and then Q8W, or placebo Q4W.
Disclosures: This study was funded by Janssen Research & Development, LLC. Some of the authors declared receiving grants, consulting fees, and speaker’s bureau support from various sources including Janssen. Seven of the authors declared being employees and stockholders of Johnson & Johnson.
Source: Rahman P et al. Arthritis Res Ther. 2021 Jul 14. doi: 10.1186/s13075-021-02554-3.
Key clinical point: Guselkumab 100 mg every 4 weeks (Q4W) or 8 weeks (Q8W) provided a clinically meaningful reduction in fatigue in patients with active psoriatic arthritis (PsA).
Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W (63%; P less than .001) and Q8W (54%; P less than .01) vs placebo (35%) achieved 4-point or higher improvement in Functional Assessment of Chronic Illness Therapy-Fatigue scores in DISCOVER-1. Findings were similar with guselkumab Q4W (60%; P less than .01) and Q8W (61%; P less than .001) vs placebo (46%) in DISCOVER-2. Improvements were maintained until week 52.
Study details: Findings are from the analysis of 2 phase 3 trials (DISCOVER 1 and DISCOVER 2) including 1,120 patients with active PsA who were randomly assigned to guselkumab 100 mg at week 0 and then Q4W, guselkumab 100 mg at weeks 0 and 4 and then Q8W, or placebo Q4W.
Disclosures: This study was funded by Janssen Research & Development, LLC. Some of the authors declared receiving grants, consulting fees, and speaker’s bureau support from various sources including Janssen. Seven of the authors declared being employees and stockholders of Johnson & Johnson.
Source: Rahman P et al. Arthritis Res Ther. 2021 Jul 14. doi: 10.1186/s13075-021-02554-3.